Medicure Inc. (CVE:MPH – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as C$2.61 and last traded at C$2.59, with a volume of 7300 shares. The stock had previously closed at C$2.59.
Medicure Price Performance
The company has a market cap of C$26.09 million, a P/E ratio of -3.47 and a beta of 0.93. The firm’s 50-day moving average is C$1.52 and its two-hundred day moving average is C$1.27. The company has a debt-to-equity ratio of 6.02, a current ratio of 0.97 and a quick ratio of 1.28.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Featured Stories
- Five stocks we like better than Medicure
- American Eagle Goes on Sale: Is It Time to Buy?
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
